Development of a Recombinant Omicron BA.1 Subunit Vaccine Candidate in Pichia pastoris.

Development of a Recombinant Omicron BA.1 Subunit Vaccine Candidate in Pichia pastoris.

Publication date: Jan 01, 2025

Low-cost and safe vaccines are needed to fill the vaccine inequity gap for future pandemics. Pichia pastoris is an ideal expression system for recombinant protein production due to its cost-effective and easy-to-scale-up process. Here, we developed a next-generation SARS-CoV2 Omicron BA. 1-based recombinant vaccine candidate expressed in P. pastoris. The receptor binding domain of Omicron BA. 1 spike protein (RBD-Omicron) was produced at 0. 35 g/L in supernatant. With a 60% recovery after two-step purification, RBD-Omicron showed 99% purity. After in vitro characterisation of purified RBD-Omicron via chromatography, mass spectrometry, calorimetry and surface plasmon resonance-based methods, it was injected into mice for immunization studies. Three different doses of Alum and CpG adjuvanted RBD-Omicron were investigated and 10 μg RBD-Omicron gave the highest antigenicity. After two doses of vaccination, IgG titers in mice serum reached to more than 10. These serum antibodies also recognized earlier (Delta Plus: B. 1.617. 2) and later (Eris: EG. 5, Pirola: BA. 2.86) SARS-CoV2 variants. The long-term immunological response in mice was measured by analyzing serum antibody titers and T-cell response of splenocytes after 60 weeks. Interestingly, IgG titers and Th1 response were significantly high even after a year. Omicron subvariants are dominantly circulating in the world, so Omicron sub-lineage-based vaccines can be used for future pandemics. The RBD-Omicron-based vaccine candidate developed in this study is suitable for technology transfer and transition into the clinic.

Open Access PDF

Concepts Keywords
60weeks Adjuvants, Immunologic
Biotechnol Adjuvants, Immunologic
Easy Animals
Pastoris Antibodies, Neutralizing
Vaccine Antibodies, Neutralizing
Antibodies, Viral
Antibodies, Viral
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
COVID‐19 vaccine
Female
Humans
Immunoglobulin G
Immunoglobulin G
Mice
omicron BA.1
Pichia
Pichia pastoris
Recombinant Proteins
Recombinant Proteins
Saccharomycetales
SARS-CoV-2
SARS‐CoV‐2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Vaccine Development
Vaccines, Subunit
Vaccines, Subunit
Vaccines, Synthetic
Vaccines, Synthetic

Semantics

Type Source Name
disease IDO protein
disease IDO production
disease IDO process
disease IDO cell
disease MESH COVID 19
drug DRUGBANK Stavudine
disease MESH severe acute respiratory syndrome
disease IDO host
disease MESH Hepatitis
disease MESH influenza
drug DRUGBANK Aluminum hydroxide
drug DRUGBANK Glycerin
drug DRUGBANK Oxygen
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Sulodexide
drug DRUGBANK Medical air
drug DRUGBANK Biotin
drug DRUGBANK Mannitol
drug DRUGBANK Water
drug DRUGBANK Coenzyme M
drug DRUGBANK Acetate ion
drug DRUGBANK Titanium
drug DRUGBANK Flunarizine
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Tromethamine
drug DRUGBANK Glycine
drug DRUGBANK Sodium acetate
pathway REACTOME Digestion
drug DRUGBANK Albendazole
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Trypsin
drug DRUGBANK Methyl isocyanate
drug DRUGBANK Formic Acid
disease IDO assay
drug DRUGBANK Sodium carbonate
disease IDO facility
disease IDO pathogen
disease IDO blood
drug DRUGBANK Ademetionine
drug DRUGBANK Iron
drug DRUGBANK L-Glutamine
drug DRUGBANK Streptomycin
drug DRUGBANK Ranitidine
disease MESH Dissociation
drug DRUGBANK Proline
disease IDO infectivity
disease IDO virulence
drug DRUGBANK Fenamole
disease MESH Infection
disease MESH Infectious Diseases
disease MESH Pneumonia
pathway REACTOME Signal Transduction

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *